4 years ago

Vaccitech Secures $168M Series B to Advance Immunotherapy Pipeline

  • Oxford-based Vaccitech, the startup behind AstraZeneca's COVID-19 vaccine, has raised $168 million in Series B funding

  • The round was led by M&G Investment Management with participation from new and existing investors

  • The funding will support the development of Vaccitech's infectious disease and immuno-oncology programs, including clinical trials for chronic hepatitis B, HPV infection, and prostate cancer.

      • ProblemHealthcare

      "Many people suffer from chronic diseases like hepatitis B, HPV infection, and cancer, and there is a need for effective new treatments."

      Solution

      "Vaccitech is developing a new immunotherapy platform that uses a combination of modified simian adenoviral vectors and the Modified Vaccinia Ankara virus to prime and boost the immune response against cells infected with a virus or tumor cells. This approach has been shown to drive powerful immune responses, including the leading CD8+ T cell stimulation profile in humans."

      Covered on